Medication Information & Disclosures
At Virtual WeightCare, our goal is to provide safe, evidence-based medical weight management under the supervision of licensed healthcare providers. This page explains the medication options that may be available through our programs and important information patients should understand before enrolling.
Clinical Evaluation Required
All patients must complete a clinical evaluation with a licensed medical provider before any medication is prescribed. Enrollment in a program and payment for services do not guarantee a prescription. A provider will review your medical history, current medications, health conditions, and treatment goals to determine whether GLP-1 therapy is clinically appropriate.Subscribers determined by provider upon the initial consultation not to be eligible for GLP-1 treatment will be approved for a full refund (minus $30 admin fee).
Compounded GLP-1 Medication Disclosure
Virtual WeightCare may coordinate access to compounded GLP-1 medication options, including compounded semaglutide or compounded tirzepatide, only when prescribed by an independent licensed medical provider and when clinically appropriate.
Required disclosure: Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before they are provided to patients. Compounded semaglutide and tirzepatide are not FDA-approved generics. Our partner compounded pharmacies are licensed and regulated in their respective states.
The FDA has stated that compounded drugs should generally be used only when a patient’s medical needs cannot be met by an FDA-approved medication. Your licensed provider will determine whether a compounded medication is appropriate based on your medical history, treatment goals, availability, and clinical judgment.
Medication is not guaranteed. Dose, formulation, pharmacy availability, state availability, and eligibility may vary. Patients should use compounded GLP-1 medications only as prescribed and should carefully follow all dosing, storage, and administration instructions. Injectable GLP-1 medications may require refrigeration, and patients should not use medication that arrives warm, damaged, mislabeled, or otherwise concerning.
Patients should promptly contact their licensed provider directly or through the Virtual WeightCare support team with medication questions, side effects, dosing concerns, or concerns about product quality. For urgent symptoms such as severe abdominal pain, persistent vomiting, signs of dehydration, allergic reaction, chest pain, fainting, or suicidal thoughts, seek urgent or emergency medical care.
GLP-1 Access Plan
The GLP-1 Access Plan focuses on provider evaluation, prescription coordination, and ongoing support. Medication is not included with this plan.
Services may include:
- Provider consultation
- Prescription coordination when clinically appropriate
- Monthly follow-up visits
- Nutrition and side effect support
- One initial prior authorization submission for eligible insurance plans, and once every 90 days if necessary.
The following are not included:
- Medication costs
- Insurance copays
- Laboratory costs
- Appeals
- Additional prior authorization resubmissions within 90 days of last submission.
Patients may use their own pharmacy when applicable.
GLP-1 Essential Plan
The GLP-1 Essential Plan includes access to compounded semaglutide and tirzepatide options when clinically appropriate and prescribed by your provider.
Medication options may include:
- Compounded semaglutide (oral or injectable, any dose)
- Compounded tirzepatide injectable (up to 8.5mg)
The plan also includes provider oversight, monthly follow-up visits, refill coordination, and ongoing support.
Additional Provider Visits
The GLP-1 Essential Plan includes monthly follow-up visits. Additional provider visits requested or required outside of the included monthly follow-up schedule are billed at $69 per visit. Additional medication supply costs may apply when applicable.
GLP-1 Advanced Plan
The GLP-1 Advanced Plan includes access to higher-dose compounded tirzepatide supply when clinically appropriate and prescribed.
Medication options may include:
- Compounded tirzepatide injectable (7.5mg or higher)
Treatment decisions, dosage adjustments, and medication recommendations are determined solely by your licensed healthcare provider.
GLP-1 Oral Plan
The GLP-1 Oral Plan includes access to compounded oral sublingual semaglutide when clinically appropriate and prescribed.
Medication options may include:
- Compounded oral semaglutide
Eligibility, dosing, and treatment recommendations are determined by your licensed healthcare provider following clinical evaluation.
Prescription Eligibility
Certain medical conditions, medications, and risk factors may make GLP-1 therapy inappropriate for some individuals. A provider may determine that GLP-1 treatment is not medically appropriate based on your medical history, current medications, clinical evaluation, or other factors. Prescription approval is never guaranteed.
Important Notice
By enrolling in a Virtual WeightCare program, you acknowledge that payment does not guarantee a prescription. A licensed medical provider will determine whether treatment is clinically appropriate based on your individual medical needs and health history. Full refunds are provided, minus a $30 admin fee, if you are determined to be ineligible upon initial video consultation.